AIPBAND
University College London (United Kingdom) - Imperial College of Science Technology and Medicine (United Kingdom) - Stockholms Universitet (Sweden) - Karolinska Institutet (Sweden) - Istituti Fisioterapici Ospitalieri (Italy) - Università degli Studi di Catania (Italy) - Scriba Nanotecnologie SRL (Italy) - Medical Trials Analysis Italy SRL (Italy) - The Hyve B.V. (Netherlands) - Stichting Katholieke Universiteit (Netherlands) - Katholieke Universiteit Leuven (Belgium)
Abstract
The mission of AiPBAND is to train a new generation of entrepreneurial and innovative early-stage researchers (ESRs) in the early diagnosis of brain tumours using molecular biomarkers in the blood, meeting the medical and societal challenges of this emerging field. AiPBAND will focus on gliomas, a range of devastating and progressive brain tumours affecting around 25.000 people each year in Europe and responsible for the majority of deaths from primary brain tumours.
